Welcome to our dedicated page for Dss SEC filings (Ticker: DSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DSS, Inc. filings document the company's public-company reporting, securities registrations, capital structure, and material events for a New York corporation with common stock listed on NYSE American. Registration statements cover common-stock offering mechanics, issuer classification, and Securities Act disclosure for financing activity.
Form 8-K filings report shareholder voting results, director elections, auditor changes, material agreements, debt-conversion arrangements involving Impact Biomedical, and other capital-structure matters. The filing record also includes audit and going-concern disclosure tied to annual reporting, along with governance and operating-result categories relevant to DSS's diversified segments.
DSS, Inc. insider transaction summary: On 08/20/2025 the company issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The stated conversion would equate to 581,395 shares.
Reporting person and ownership: The filing is by Heng Fai Ambrose Chan and Alset Inc.; Mr. Chan is identified as a director and a greater-than-10% owner. The filing discloses Mr. Chan's total beneficial ownership of 6,730,059 shares, detailed by holdings across Heng Fai Holdings Limited, direct holdings, Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.
DSS, Inc. Schedule 13D/A shows that Heng Fai Ambrose Chan and affiliated entities control a large majority of the company’s common stock. Together they beneficially own 6,730,059 shares, representing 69.6% of the 9,092,518 shares outstanding as of August 21, 2025. Alset Inc. alone holds 4,542,606 shares (47.0%). On August 20, 2025, DSS issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The filing lists the ownership breakdown across Heng Fai Holdings Limited, Alset entities and Global Biomedical, and cites a joint filing agreement as an exhibit.